Nicole M Haynes
Dr Nicole Haynes is an experienced tumour immunologist. She is Science Lead of Immuno-oncology at Cancer Therapeutics (CTx); a small molecule drug discovery company supported by the Cooperative Research Centres (CRC) Program. Dr Haynes manages the development, execution and analysis of in vitro and in vivo biological assay systems used to study the immune modulatory effects and mechanisms of action of novel anti-cancer drugs. In addition to her work with CTx, Dr Haynes also directs an independent research team within the Peter Mac research division. Her lab focuses on the preclinical development and testing of novel immunotherapy-based combination therapies for the treatment of solid cancers. Moreover, her group has built an innovative radiation immuno-oncology platform at the Peter Mac, which has led to the establishment of formal collaborations with pharmaceutic companies testing novel immunotherapeutic drugs in combination with radiation therapy. Dr Haynes is actively working with clinical colleagues at the Peter Mac to move these therapeutic approaches into clinical trial.
Abstracts this author is presenting: